(Date:5/15/2008)...-869 to be Promising in Targeting Cancer Cells, ...TT PARK, Ill., May 15 /PRNewswire-FirstCall/ -- Ab... trial data of several investigative,compounds in ...rican,Society of Clinical Oncology (ASCO) Annual M...ntations include ABT-263, a Bcl-2 family protein,a...
(Date:5/15/2008)...inhua-PRNewswire-FirstCall/ -- China Yingxia,Inter...Yingxia" or "the,Company"), a leading provider in ...ent, manufacture and distribution of organic nutri...re products in the People,s Republic,of China ("PR...first,quarter ended March 31, 2008., First Quar...
(Date:5/15/2008)... goal of tailoring cancer treatment for each indiv...l Center today presented a study suggesting a simp...s treatment efficacy for patients with metastatic ...ometimes months to determine if a particular cance...ng to observe any significant radiographic changes...
(Date:5/15/2008)...n called IGF-1R in patients with gastrointestinal ...ient would be less responsive to the drug imatinib...K. Godwin, Ph.D., a researcher at the Fox Chase Ca...have shown that GIST cells, especially Gleevec-res...lopment for treatment-resistant breast cancer, a f...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Protein predicts Gleevec resistance in gastrointestinal tumors 2...cipate seizures in children with epilepsy.The most...udy was // licking, often of the face, followed b...ctive" behavior without aggression. In previous st...that licking may abort or even prevent their seizu...
...feeling sick and with a number of other side effec...tment // and all they go through with it may not e...ng a new, more targeted approach to delivering che... aggressive way available to deliver chemotherapy ...
...icles and cause prostate cancer cells to grow. Low...shrink or grow more slowly. However, hormone thera... other treatments such as surgery or radiation are...common treatment for prostate cancer significantly...
...atment proves to be the best option to substantial...gery to remove part of the affected vein in additi...new treatment option for leg ulcers .Surgery did n...ms of venous ulcer healing, but recurrence rates w...
Other Medicine News:(Date:5/15/2008)...s for an Antiplatelet Therapy that, Combined, with...n of Plavix/Iscover and Aspirin, According to ...ss., May 15 /- Decision Resources, on...ms for pharmaceutical and,healthcare issues, finds...provement in patient compared to Sanofi-Aventis/Br...
(Date:5/15/2008)...fter CEA Trial data reports in third quarter ...y 15 /- VIA Pharmaceuticals...ocused on the development of,compounds for the tre...that,it has completed patient enrollment in its ac...s one of three Phase 2 trials investigating VIA-22...
(Date:5/15/2008)... Annual Meeting of The American Society of ...-, IRVINE, Calif., May 15 /PRNewswire-FirstCall/ ... today announced the presentation of updated data,...amurtide (L-MTP-PE) in,patients with lung metastas... a rare and often fatal bone tumor that typically ...
(Date:5/14/2008)... /- Progen,Pharmaceuticals ...at the,Company has resumed patient enrolment in th...quired polyamine analogue, PG-11047 (formerly CGC-... has commenced development of PG-11047 - the lead ...am - following its acquisition of,Cellgate, Inc ea...
Breaking Medicine Technology:Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2CoAxia 28TM 29 Announces 2411 5M Equity Financing From Existing Investors 1669 1CoAxia 28TM 29 Announces 2411 5M Equity Financing From Existing Investors 1669 2Avandia May Slow Atherosclerosis After Bypass Surgery 15707 1Avandia May Slow Atherosclerosis After Bypass Surgery 15707 2Avandia May Slow Atherosclerosis After Bypass Surgery 15707 3NASA launches airborne study of arctic atmosphere air pollution 2708 1NASA launches airborne study of arctic atmosphere air pollution 2708 2NASA launches airborne study of arctic atmosphere air pollution 2708 3Daytime TV Addresses the Onslaught of MRSA Cases in U S 15703 1Daytime TV Addresses the Onslaught of MRSA Cases in U S 15703 2... Statistically Significant Changes in,Agitation Le...6, 2007 /PRNewswire-FirstCall/ --,Alexza Pharmaceu...lts from its Phase IIa clinical trial of AZ-004 (S...h acute agitation. The 10 mg,dose of AZ-004 met th...s a statistically-significant reduction in the mea...
...esented at Keystone Scientific Meeting, SOUTH SAN ...tCall/ -- Rigel today announced that Yonchu,Jenkin...presenting,on the company,s efforts to develop a s...he Human Immunodeficiency Virus (HIV),infection at...ch,27th and 29th. Dr. Jenkins will present both a ...
Other Medicine Technology:Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 2Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 3Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 4Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 5Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 6Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV,Activity 2Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV,Activity 3The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets.
The lower body blanket is utilized during surgical procedures covering the head, neck, arms and upper torso of your patient.
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively.
This blanket is ideal for warming the large child or small adult during upper body surgery.
Medicine Products: